Piperacillin + Tazobactam

# Piperacillin + Tazobactam ## Overview - **Classification**: Extended-spectrum penicillin antibiotic + Beta-lactamase inhibitor - **Mechanism**: Piperacillin inhibits bacterial cell wall synthesis. Tazobactam protects piperacillin from enzymatic degradation by many beta-lactamases, extending its spectrum. ## Primary Indications 1. **Nosocomial Pneumonia** - Including ventilator-associated 2. **Complicated Intra-abdominal Infections** - Including appendicitis, peritonitis 3. **Complicated Skin and Skin Structure Infections** - Including cellulitis, abscesses 4. **Gynecological Infections** - Endometritis, pelvic inflammatory disease 5. **Febrile Neutropenia** - Empiric therapy ## Adult Dosing ### Standard Dosing **Most Infections (e.g., Intra-abdominal, Skin/Skin Structure)** - **Dose**: **3.375 g IV** (3 g piperacillin / 0.375 g tazobactam) - **Frequency**: Every 6 hours - **Route**: Intravenous infusion over 30 minutes - **Duration**: 5-14 days, depending on infection type and severity **Nosocomial Pneumonia, Febrile Neutropenia (Empiric), Severe Infections** - **Dose**: **4.5 g IV** (4 g piperacillin / 0.5 g tazobactam) - **Frequency**: Every 6 hours - **Route**: Intravenous infusion over 30 minutes - **Maximum Dose**: **18 g piperacillin per day** (20.25 g combined product) - **Special Consideration**: Extended infusion (e.g., **3.375 g over 3-4 hours q8h** or **4.5 g over 3-4 hours q8h**) may be used for severe infections to optimize pharmacodynamics. ### Dose Adjustments - **Renal Impairment**: Based on creatinine clearance (CrCl) - **CrCl 20-40 mL/min**: **2.25 g IV q6h** or **3.375 g IV q8h** - **CrCl < 20 mL/min**: **2.25 g IV q8h** - **Hemodialysis (HD)**: **2.25 g IV q8h** + **0.75 g IV post-dialysis** on HD days - **Hepatic Impairment**: No specific adjustment recommended; monitor closely for adverse effects. - **Elderly Patients**: Adjust dose based on renal function, typically no age-specific adjustment needed otherwise. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Individualized, generally **not recommended** due to limited data, potential for benzyl alcohol toxicity (some formulations), and bilirubin displacement by tazobactam. - **Special Notes**: **Consult infectious disease specialist** for guidance if use is considered. ### Infants (1-9 months) - **Indication**: Serious infections - **Dose**: **90 mg/kg/dose** (piperacillin component) - **Frequency**: Every 6 hours - **Route**: Intravenous infusion over 30 minutes - **Maximum**: **4 g piperacillin per dose** (equivalent to 4.5 g combined product) ### Children (9 months-12 years) - **Indication**: Mild-to-moderate infections (e.g., complicated appendicitis) - **Dose**: **80 mg/kg/dose** (piperacillin component) - **Frequency**: Every 6 hours - **Route**: Intravenous infusion over 30 minutes - **Maximum**: **4 g piperacillin per dose** (equivalent to 4.5 g combined product) - **Indication**: Severe infections (e.g., febrile neutropenia, nosocomial pneumonia) - **Dose**: **90 mg/kg/dose** (piperacillin component) - **Frequency**: Every 6 hours - **Route**: Intravenous infusion over 30 minutes - **Maximum**: **4.5 g piperacillin per dose** (equivalent to 5.0625 g combined product) ### Adolescents (13-18 years) - **Dose**: Use **adult dosing regimens**. - **Maximum**: **18 g piperacillin per day** (20.25 g combined product) ## Safety Information ### Contraindications - **Absolute**: History of severe hypersensitivity reaction (e.g., anaphylaxis, SJS) to any penicillin, cephalosporin, other beta-lactamase inhibitors, or other components of the formulation. ### Common Adverse Effects - **Very Common (>10%)**: Diarrhea - **Common (1-10%)**: Nausea, vomiting, rash, headache, constipation, insomnia, elevated LFTs, phlebitis at injection site - **Serious but Rare**: Anaphylaxis, *Clostridioides difficile* associated diarrhea (CDAD), seizures (especially in renal impairment), thrombocytopenia, leukopenia, neutropenia, interstitial nephritis, SJS/TEN. ### Key Drug Interactions - **Warfarin**: May increase INR and risk of bleeding. **Monitor INR** closely. - **Aminoglycosides**: Inactivation when mixed directly *in vitro*. Administer separately at different sites/times. - **Methotrexate**: May decrease methotrexate clearance. **Monitor methotrexate levels** and for toxicity. - **Vecuronium**: Can prolong neuromuscular blockade. **Monitor patient carefully**. - **Probenecid**: Increases and prolongs piperacillin and tazobactam levels. No dose adjustment typically needed. ## Monitoring & Follow-up - **Before Treatment**: Obtain allergy history, assess renal function (CrCl), baseline CBC. - **During Treatment**: - **Renal function**: Monitor CrCl daily/every other day in severe renal impairment. - **CBC**: Weekly for prolonged therapy (>10 days) due to risk of neutropenia/thrombocytopenia. - **LFTs**: Periodically. - **Electrolytes**: Monitor potassium due to risk of hypokalemia. - **Clinical Signs**: Monitor for resolution of infection, fever, rash, C. difficile symptoms, neurological changes (seizures). ## Clinical Pearls - 💡 **Extended Infusion**: Consider 3-4 hour extended infusions for severe infections, particularly with resistant organisms, to optimize bacterial kill. - 💡 **Sodium Content**: Each gram of piperacillin contains approximately **2.35 mEq of sodium**. Consider in patients with fluid restrictions or hypertension. - 💡 **Compatibility**: Do NOT mix with Ringer's lactate or Dextrose containing solutions with Sodium Bicarbonate, or blood products/albumin. - 💡 **Drug-induced Fever**: Can cause drug fever, which typically resolves after discontinuation. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.